Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jan 20;27(3):433-8.
doi: 10.1200/JCO.2008.18.5546. Epub 2008 Dec 8.

BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma

Cristina R Ferrone  1 , Douglas A Levine, Laura H Tang, Peter J Allen, William Jarnagin, Murray F Brennan, Kenneth Offit, Mark E Robson
Affiliations

BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma

Cristina R Ferrone et al. J Clin Oncol. .

Abstract

Purpose: The prognostic significance of germline BRCA1 and BRCA2 mutations in Jewish patients with pancreatic adenocarcinoma (PAC) is unknown. Our objective was to define the prevalence of BRCA1 and BRCA2 in an unselected group of Jewish patients and to compare the clinical characteristics and overall survival (OS) of patients with resected BRCA mutation-associated PAC to PAC patients without mutations.

Patients and methods: Jewish patients with PAC resected between January 1986 and January 2004 were identified. DNA was extracted from the archived material, anonymized, and genotyped for founder mutations in BRCA1 (185delAG, 5382insC) and BRCA2 (6174delT). Standard two-sided statistical tests were utilized.

Results: Of the 187 Jewish patients who underwent resection for PAC, tissue was available for 145 patients. Eight subjects (5.5%) had a BRCA founder mutation (two with BRCA1 [1.3%], six with BRCA2 [4.1%]). The BRCA2 founder mutation was identified in 4.1% of patients with pancreatic adenocarcinoma compared with only 1.1% of cancer-free Washington, DC,-area controls (4.1% v 1.1%; P = .007; odds ratio, 3.85; 95% CI, 2.1 to 10.8). Patients with and without BRCA1 or BRCA2 mutations did not differ in age (mean, 66 v 73 years; P = .6) or other clinicopathologic features. OS was not significantly different (median, 6 v 16 months; P = .35). A previous cancer was reported by 24% (35 of 145) of patients with the most common sites being breast cancer (9 of 35; 74%) and prostate cancer (8 of 35; 23%).

Conclusion: Founder mutations for BRCA1 and BRCA2 were identified in 5.5% of Ashkenazi patients operated on for PAC. BRCA2 mutations were more prevalent than documented by population studies. Consistent with previous reports, BRCA2 mutations are associated with an increased risk of PAC.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Overall survival of patients stratified by BRCA mutation.
See this image and copyright information in PMC

References

    1. Thull DL, Vogel VG: Recognition and management of hereditary breast cancer syndromes. Oncologist 9:13-24, 2004 - PubMed
    1. Hartge P, Struewing JP, Wacholder S, et al: The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64:963-970, 1999 - PMC - PubMed
    1. Robson M, Dabney MK, Rosenthal G, et al: Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test 1:47-51, 1997 - PubMed
    1. Robson M, Rajan P, Rosen PP, et al: BRCA-associated breast cancer: Absence of a characteristic immunophenotype. Cancer Res 58:1839-1842, 1998 - PubMed
    1. Robson ME, Offit K: New BRCA2 mutation in an Ashkenazi Jewish family with breast and ovarian cancer. Lancet 350:117-118, 1997 - PubMed